Analyst Price Target is $47.25
▲ +41.85% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Neurogene in the last 3 months. The average price target is $47.25, with a high forecast of $61.00 and a low forecast of $31.00. The average price target represents a 41.85% upside from the last price of $33.31.
Current Consensus is
Buy
The current consensus among 6 polled investment analysts is to buy stock in Neurogene. This Buy consensus rating has held steady for over two years.
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Read More